[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"glioma-intracranial\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:glioma-intracranial":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,88],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100481940","early-phase-1-evaluation-of-18f-fluciclovine-positron-emission-tomography---magnetic-resonance-imaging-pet-mri-in-lgg-100481940",false,"NCT05555550","Evaluation of 18F-Fluciclovine Positron Emission Tomography - Magnetic Resonance Imaging (PET-MRI) in LGG","Evaluation of 18F-Fluciclovine PET-MRI as a Biomarker of Response in Pediatric and Young Adult Patients With Low Grade Gliomas (LGG)","Inclusion Criteria\n\n1. LGG including the brainstem and supratentorial only (WHO grade I-II), confirmed by biopsy unless in NF1 participants with classic appearance.\n2. Participants must have evaluable disease (1x1 cm tumor on MRI)\n3. Scheduled to receive systemic therapy for LGG\n4. Performance Score: Karnofsky ≥ 50 for participants \\> 16 years of age and Lansky ≥ 50 for participants ≤ 16 years of age. Participants who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.\n5. Age: Participants must be ≥ 1 years but ≤21 years of age at registration\n6. Being on a treatment regimen does not exclude a subject from enrollment.\n\nExclusion Criteria\n\n1. Inability to tolerate imaging procedures in the opinion of an investigator or treating physician\n2. Pregnant participants\n3. Participants who weigh less than 8 kg.\n4. Participants who cannot avoid contact with a pregnant woman or infant for at least 12 hours following injection.\n5. Participants with a history of abnormal kidney function or creatinine \\>= CTCAE v5.0 grade 2 at time of study registration.\n6. Participants with primary tumors of the spinal cord.","ALL","1 Year","21 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"EARLY_PHASE1","The purpose of this study is to see if 18F-Fluciclovine (Axumin®) is useful and safe in the management of children with Low Grade Gliomas (LGG). Imaging with 18F-Fluciclovine PET-MRI will be performed prior to initiation of therapy for LGG, and then 3 months, and 1 year after starting therapy. Changes in 18F-Fluciclovine uptake will be compared to changes in MRI measurements at 3 months and 1 year as compared to baseline.",[27,28,29,30,31],"Glioma","Low-grade Glioma","Low Grade Glioma of Brain","Glioma, Malignant","Glioma Intracranial",[27,28,29,30,31,33],"18F-Fluciclovine","RECRUITING","2026-04-24",{"date":37,"type":38},"2026-04-29","ACTUAL",{"date":40,"type":21},"2026-07-29",{"date":42,"type":21},"2027-09",{"name":44,"class":45},"Children's Hospital of Philadelphia","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":59,"conditions":60,"keywords":65,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":86,"locationsCount":4},"100419702","a-study-using-brain-stimulation-and-behavioral-therapy-to-increase-extent-of-resection-in-low-grade-gliomas-100419702","NCT04745156","A Study Using Brain Stimulation and Behavioral Therapy to Increase Extent of Resection in Low-Grade Gliomas","Inducing Functional Plasticity in Glioma-Involved Functional Cortex With Deficit-Inducing Cortical Stimulation and Targeted Behavioral Therapy to Increase Extent of Resection","Inclusion Criteria:\n\n1. Age 18-65 years old\n2. Ability to understand a written informed consent document, and the willingness to sign it\n3. Radiographic evidence of likely low-grade glioma on MRI (i.e. non-enhancing) invading primary motor cortex in the non-dominant hemisphere.\n4. Karnofsky performance status (KPS) ≥ 75\n5. Normal or near normal motor strength (i.e., at least 3\u002F5 in relevant areas)\n6. Normal or near normal speech (Can consistently name at least 4\u002F5 cards)\n7. No medical contraindication to surgery\n8. Free of other illness that may shorten life expectancy\n\nExclusion Criteria:\n\n1. Presence of other malignancy not in remission\n2. Evidence of bi-hemispheric or widespread tumor involvement\n3. Likely candidate to receive GTR on initial resection\n4. Medically high-risk surgical candidate\n5. History of recent scalp or systemic infection\n6. Presence of other implants or foreign bodies in the head\n7. Inability to receive an MRI for any reason\n8. Inability to receive cortical stimulation for any reason\n9. Coagulation disorders and\u002For use of anti-thrombotic therapies\n10. Platelet count \\\u003C 50\n11. Diathermy procedures\n12. Electroconvulsive Therapy (ECT)\n13. Transcranial Magnetic Stimulation (TMS)\n14. Presence of implanted cardiac device (such as a pacemaker or defibrillator)\n15. Pregnant women","18 Years","65 Years",{"count":5,"type":21},[58],"NA","This study uses a cranial implant to deliver cortical stimulation that, when paired with physiotherapy, will remap the brain so that critical brain functions can be protected during brain tumor surgery. This pilot study will provide initial evidence for the safety and feasibility of such a protocol which will lead to future pivotal trials that could radically change eloquent area brain surgery. For patients with otherwise incompletely resectable brain tumors, this could mean a longer life expectancy and a better quality of life.",[27,31,61,62,63,64],"Gliomas Benign","Brain Tumor","Brain Cancer","Motor Cortex; Lesion",[66,67,68,69,70,71,72,73,74,75,76,77,78],"Brain Stimulation","NeuroPace","Cortex Stimulation","Neuroplasticity","Plasticity","Hand Motor Cortex","Primary Motor Cortex","M1","Motor Mapping","Resection","Surgery","Motor Rehabilitation","Prehabilitation","NOT_YET_RECRUITING","2026-01-09",{"date":82,"type":38},"2026-01-12",{"date":84,"type":21},"2026-08-01",{"date":42,"type":21},{"name":87,"class":45},"Medical College of Wisconsin",{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":4,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":95,"targetDuration":4,"studyType":22,"phases":96,"briefSummary":97,"conditions":98,"keywords":101,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":46},"100481748","early-phase-1-18f-fluciclovine-pet-mri-in-high-grade-glioma-100481748","NCT05553041","18F-Fluciclovine PET-MRI in High-grade Glioma","Evaluation of 18F-Fluciclovine PET-MRI to Differentiate Tumor Progression From Post-treatment Changes in Pediatric High-grade Glioma (HGG)","Inclusion Criteria\n\n* 1\\. Histopathology-proven HGG (WHO grade III-IV) or DMG (WHO grade IV) or, in the case of DMG of the pons, imaging that is characteristic of Diffuse intrinsic pontine gliomas (DIPG) (diffusely infiltrating \\>=2\u002F3 of the pons).\n* 2\\. Measurable disease, measuring at least 1x1 cm.\n* 3\\. Life expectancy of greater than 8 weeks.\n* 4\\. Age \\> 1 years but \\< 21 years of age at enrollment.\n\nFor those without planned surgery:\n\n* 1\\. Participants with clinical and\u002For radiographic suspicion of True progression (TP) or Pseudoprogression (PsP) during radiation but yet to have the initial post-radiation MRI scan.\n\nor\n\n* 2\\. Participants with suspicion for TP or PsP on first post-radiation MRI\n\nFor those with planned surgery:\n\n* 1\\. Clinical or radiographic suspicion of tumor progression with plan to undergo surgery or biopsy.\n\nExclusion Criteria:\n\n* 1\\. Inability to tolerate imaging procedures in the opinion of an investigator or treating physician.\n* 2\\. Pregnant or breastfeeding participants.\n* 3\\. Participant who would require sedation or anesthesia for imaging beyond standard of care (SOC).\n* 4\\. Participants who weigh less than 8 kg.\n* 5\\. Participants who cannot avoid contact with a pregnant woman or infant for at least 12 hours following injection.\n* 6\\. Participants with a history of abnormal kidney function or creatinine \\>= CTCAE v5.0 grade 2 at time of study registration.\n\n  7\\. Participants with primary tumors of the spinal cord.",{"count":20,"type":21},[24],"The purpose of this study is to see if 18F-fluciclovine (Axumin®) PET imaging is useful and safe in the management of children with High Grade Gliomas. Investigators seek to determine if this imaging will help doctors tell the difference between tumor growth (progression) and other tumor changes that can occur after treatment.",[27,99,30,31,100],"High Grade Glioma","Diffuse Glioma",[27,99,30,31,100,102],"18F fluciclovine","2025-12-03",{"date":105,"type":38},"2025-12-04",{"date":107,"type":38},"2024-08-07",{"date":109,"type":21},"2027-12",{"name":44,"class":45}]